Predictive and prognostic markers for epidermal growth factor receptor inhibitor therapy in non-small cell lung cancer. - Wikidata - awgldk - TriplyDB

Predictive and prognostic markers for epidermal growth factor receptor inhibitor therapy in non-small cell lung cancer.

Predictive and prognostic markers for epidermal growth factor receptor inhibitor therapy in non-small cell lung cancer.

http://www.wikidata.org/entity/Q35076206

about

The Difference of Clinical Characteristics Between Patients With Exon 19 Deletion and Those With L858R Mutation in Nonsmall Cell Lung Cancer.Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer.Kinase dysfunction and kinase inhibitors.Classification of lung cancer histology by gold nanoparticle sensors.EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma [Epidermal growth factor receptor mutations and radiotherapy in non-small cell lung cancer].Impact of heavy smoking on the benefits from first-line EGFR-TKI therapy in patients with advanced lung adenocarcinoma.

P2860

Q37026204-367918E2-999C-41E9-B02B-84238AC711D7 Q37768460-472A28AA-4AFA-434E-A381-DBB4819176F2 Q38075152-9C542C53-5E30-41A3-9A87-232D29F9B6AE Q38286916-87AD8175-009D-4A83-93A0-053BDD326C49 Q38807586-13B82FD1-C66C-4366-A16C-E16215A65A10 Q44478432-75904F0B-F27A-457D-A994-42B34F55DB06 Q54123954-13E30F77-1E02-472A-A284-599B38C69A5F

P2860

Predictive and prognostic markers for epidermal growth factor receptor inhibitor therapy in non-small cell lung cancer.

http://www.wikidata.org/entity/Q35076206

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Predictive and prognostic mark ...... in non-small cell lung cancer.

@ast

Predictive and prognostic mark ...... in non-small cell lung cancer.

@en

type

label

Predictive and prognostic mark ...... in non-small cell lung cancer.

@ast

Predictive and prognostic mark ...... in non-small cell lung cancer.

@en

prefLabel

Predictive and prognostic mark ...... in non-small cell lung cancer.

@ast

Predictive and prognostic mark ...... in non-small cell lung cancer.

@en

P1433

Q35076206-958D35D3-96A0-49AB-8EA2-37FA71990209

P1476

Q35076206-4913FEEC-6558-45C2-9AB8-E8316713E3BE

P2093

Q35076206-25A3F9C3-5348-45AB-ADDA-07897D1EEF15

Q35076206-4945B0E0-4A08-425F-9157-B299F628B3F5

Q35076206-9A35E67B-F3C3-438A-90B4-1A13C48444EC

Q35076206-C476D998-CCE9-41FC-A377-1849755EB36F

P2860

Q35076206-083CB9A3-D3F6-4EB5-9526-D633BFCDABA7

Q35076206-09666FE1-D30B-47B5-B1DB-9F5FB97FB3CA

Q35076206-09DF9F29-253F-43B6-AB76-C4A878F58EF8

Q35076206-0DA982D0-FB36-4FBF-83E6-390381ED999C

Q35076206-0EBF844E-FBF2-42BF-87AB-17657A1C8C8C

Q35076206-18714E67-AD4B-4579-8876-38314C1F542B

Q35076206-399C786A-ACD1-42EC-9893-4389DE85B496

Q35076206-39DDB919-7FC8-4205-A1EF-09F8A8AC2894

Q35076206-41A01BAC-BCC5-422D-8D5E-F26EFDBE1561

Q35076206-48F17429-E29F-4F76-B902-DEFE9C8A71C8

P304

Q35076206-F8570E46-C1FE-4F8C-8649-6B8ED9F3A653

P31

Q35076206-34A3E805-1601-4EE6-B057-EEF5A1066E77

P356

Q35076206-58123265-C6D8-4DD0-9112-85CB458F7D84

P433

Q35076206-16835695-DCD2-43CC-AF90-3BA94C23E38F

P478

Q35076206-2967B46A-C6EE-4892-929E-0817B4201819

P577

Q35076206-8D2D963D-0A4F-492E-A9C6-6E5923B7E568

P5875

Q35076206-DC61F36D-DDF4-46C7-888A-C2D21C4EBE61

P698

Q35076206-2503437C-2DF9-4173-B3A2-01A4D0E51C68

P932

Q35076206-77CEFAC7-5228-4663-BA7E-7746E02949E5

P356

1758834009347923

P1433

Therapeutic advances in medical oncology

P1476

Predictive and prognostic mark ...... in non-small cell lung cancer.

@en

P2093

Fred R Hirsch

http://www.w3.org/2001/XMLSchema#string

Koichi Yoshida

http://www.w3.org/2001/XMLSchema#string

Murry W Wynes

http://www.w3.org/2001/XMLSchema#string

Nir Peled

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

Erlotinib in previously treated non-small-cell lung cancer

Epidermal growth factor receptor mutations in lung cancer

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

P304

137-144

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1758834009347923

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2009-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51521158

http://www.w3.org/2001/XMLSchema#string

P698

21789118

http://www.w3.org/2001/XMLSchema#string

P932

3125998

http://www.w3.org/2001/XMLSchema#string